Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | AR | P10275 | 14/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17266277 | 0.79 | AR (0.61) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL4145551 | 0.78 | LMNA (0.58) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL2698786 | 0.78 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL4463690 | 0.78 | LMNA (0.68) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL20243714 | 0.78 | LMNA (0.58) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL24375919 | 0.78 | LMNA (0.58) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL3160595 | 0.78 | HTR2C (0.46) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL1436135 | 0.77 | MAPT (0.59) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| Hydrochloric Acid SCHEMBL9282405 | 0.76 | LMNA (0.57) | NPC1RAB9ASMN1; SMN2MAPK1AR | |
| SCHEMBL17014739 | 0.76 | AR (1.00) | NPC1RAB9ASMN1; SMN2MAPK1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| CN-113214246-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| CN-106795151-B | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20200262814-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2020-08-20 | — | — | US | disclosed |
| US-20200255436-A1 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-08-13 | — | — | US | disclosed |
| WO-2008083070-A1 | CRF1 RECEPTOR LIGANDS COMPRISING FUSED BICYCLIC HETEROARYL MOIETIES | NEUROGEN CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080113978-A1 | Imidazopyridazine Compounds | ELI LILLY AND COMPANY | 2008-05-15 | — | — | US | disclosed |
| WO-2008036579-A1 | THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-03-27 | — | — | WO | disclosed |
| CN-101142217-A | Imidazopyridazine compounds | LILLY CO ELI (US) | 2008-03-12 | — | — | CN | disclosed |
| EP-1869049-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | FINK CYNTHIA A | 2007-03-15 | — | — | US | disclosed |
| CN-1886378-A | 1,4-disubstituted isoquinilone derivatives as RAF-kinase inhibitors useful for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2006-12-27 | — | — | CN | disclosed |
| WO-2006102194-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-28 | — | — | WO | disclosed |
| EP-1667980-A1 | 1,4-DISUBSTITUTED ISOQUINOLINE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005028444-A1 | 1,4-DISUBSTITUTED ISOQUINILONE DERIVATIVES AS RAF-KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NPC1 892/4885RAB9A 854/4885SMN1; SMN2 3002/4885 |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NPC1 892/4885RAB9A 854/4885SMN1; SMN2 3002/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | NPC1 892/4885RAB9A 854/4885SMN1; SMN2 3002/4885 |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | NPC1 892/4885RAB9A 854/4885SMN1; SMN2 3002/4885 |
| US-20200255436-A1 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS | CRH, CRHR2, CRHR1 | NPC1 1008/4885RAB9A 1673/4885SMN1; SMN2 900/4885 |
| US-20070060582-A1 | 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases | BRAF, RAF1, NRAS | NPC1 1468/4885RAB9A 598/4885SMN1; SMN2 4098/4885 |
| US-20200262814-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NPC1 892/4885RAB9A 854/4885SMN1; SMN2 3002/4885 |
| US-20080113978-A1 | Imidazopyridazine Compounds | CRHR1, CRH, CRHR2 | NPC1 814/4885RAB9A 2305/4885SMN1; SMN2 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.